Month: August 2021

-Q2 2021 Total Net Revenues of $36.4 Million Reflect Strong Quarter over Quarter Growth -Q2 2021 GAAP Net Income of $12.2 Million; Non-GAAP Net Income of $17.4 Million -$155.3 Million in Cash and Investments and no Funded Debt at End of Q2-2021 -Catalyst to Host Quarterly Conference Call at 8:30 AM ET Tomorrow CORAL GABLES, Fla., Aug. 09, 2021 (GLOBE NEWSWIRE) — Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq:CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing and commercializing novel high-quality medicines for patients living with rare diseases, today reported financial results for the second quarter ended June 30, 2021 and provided a corporate update. “I am very pleased that our operational plan for 2021 and year to date financial results continue to deliver as originally...

NEW YORK, Aug. 09, 2021 (GLOBE NEWSWIRE) — INDUS Realty Trust, Inc. (Nasdaq: INDT) (“INDUS” or the “Company”), a U.S. based industrial/logistics REIT, today reported financial results for the three months ended June 30, 2021 (the “2021 second quarter”). 2021 Second Quarter & Recent HighlightsNet loss of $1.2 million for the 2021 second quarter compared to a net loss of $0.7 million for the three months ended June 30, 2020 (the “2020 second quarter”) Net Operating Income (“NOI”)1 of $7.3 million for the 2021 second quarter as compared to $6.8 million for the 2020 second quarter Cash NOI2 for industrial/logistics properties of $6.1 million for the 2021 second quarter as compared to $5.4 million for the 2020 second quarter Industrial/logistics portfolio was 95.3% leased; stabilized3 industrial/logistics portfolio was 99.4%...

First quarter revenue increases 45% as reported; 21% constant currency organic Cantel Medical integration on track Company increases outlook and raises quarterly dividendDUBLIN, IRELAND, Aug. 09, 2021 (GLOBE NEWSWIRE) — STERIS plc (NYSE: STE) (“STERIS” or the “Company”) today announced financial results for its fiscal 2022 first quarter ended June 30, 2021. Revenue as reported for the quarter increased 45% to $968.4 million compared with $668.9 million in the first quarter of fiscal 2021. Constant currency organic revenue (see Non-GAAP Financial Measures) increased 21% for the first quarter of fiscal 2022 as compared to the first quarter of fiscal 2021, which was negatively impacted by the pandemic.   “We are pleased to report a strong start to our new fiscal year,” said Dan Carestio, President and Chief Executive Officer of...

Monthly information regarding the total number of voting rights and total number of shares of the Company as of July 31, 2021 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers) Market : NYSE Euronext Paris ISIN Code: FR 0010417345DateTotal number of shares Total number of voting rights07/31/2021 55,011,687Total gross of voting rights: 55,011,687Total net* of voting rights: 54,942,087  * Total net = total number of voting rights attached to shares – shares without voting rights        AttachmentPDF Version

HAMILTON, BERMUDA, August 9, 2021 – DHT Holdings, Inc. (NYSE:DHT) (“DHT” or the “Company”) today announced its results for the quarter ended June 30, 2021. The full report is available here and in the below attachment. About DHT Holdings, Inc. DHT is an independent crude oil tanker company. Our fleet trades internationally and consists of crude oil tankers in the VLCC segment. We operate through our integrated management companies in Monaco, Singapore and Norway. You shall recognize us by our business approach with an experienced organization with focus on first rate operations and customer service, quality ships, prudent capital structure to accommodate staying power through the business cycles, a combination of market exposure and fixed income contracts for our fleet, a counter cyclical philosophy with respect to investments, employment...

Data published in Drugs in R&D confirms extended-release PK profile of ZILRETTA (triamcinolone acetonide extended-release injectable suspension) in patients with shoulder OA Plasma PK data indicate the total and maximal exposure to triamcinolone acetonide (TA) was approximately two-thirds lower in patients treated with ZILRETTA compared to triamcinolone acetonide in crystalline suspension (TAcs) Registration trial in patients with shoulder OA expected to begin later this yearBURLINGTON, Mass., Aug. 09, 2021 (GLOBE NEWSWIRE) — Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced that the results from the randomized, open-label, Phase 2 pharmacokinetic (PK) trial of ZILRETTA (triamcinolone acetonide extended-release injectable suspension) were published in Drugs in R&D. The study compared the plasma PK profile of ZILRETTA...

DENVER, Aug. 09, 2021 (GLOBE NEWSWIRE) — Bonanza Creek Energy, Inc. (NYSE: BCEI) (the “Company” or “Bonanza Creek”) today announced its second quarter 2021 financial results. The Company has also posted an updated investor presentation to its website. Highlights include:Paid first-ever quarterly dividend of $0.35 per share in June, representing a 3.7% annual dividend yield based on Bonanza Creek’s August 6, 2021 closing stock price Bonanza Creek Board of Directors has declared the third quarter 2021 fixed dividend of $0.35 per share will be paid on September 30, 2021 to shareholders of record at the close of business on September 15, 2021 Average sales volumes for the second quarter of 42.3 thousand barrels of oil equivalent per day (“MBoe/d”) with oil representing 49.5% of total volumes Total capital...

Company to Host Conference Call and Webcast on August 10, 2021, at 8:00 a.m. EDT SHANGHAI and SAN FRANCISCO, Aug. 09, 2021 (GLOBE NEWSWIRE) — Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), an innovative commercial-stage biopharmaceutical company, today announced financial results for the second quarter of 2021, along with recent product highlights and corporate updates. “Consistent with our past track record, Zai Lab continued to execute with speed and quality across the organization during the second quarter,” said Dr. Samantha Du, Founder, Chairperson and Chief Executive Officer of Zai Lab. “We successfully launched QINLOCK, the first product in what we hope will become a world-class gastric cancer franchise, in China; generated strong revenue growth from ZEJULA and Optune; and entered into strategic collaborations with Mirati,...

Second Quarter 2021 OverviewConsulting Fee Revenue (“CFR”) rose to $77.7 million from $75.8 million in the prior year period New contract awards increased 29.1% to $90.4 million from $70.0 million in the prior year period, resulting in a book-to-burn ratio of 116.4% Backlog increased to $672.3 million at June 30, 2021, up from December 31, 2020 Net loss narrowed to $(0.5) million, or $(0.01) per diluted share, compared to net loss of $(2.0) million, or $(0.03) per diluted share in the prior year period Adjusted EBITDA (a non-GAAP measure) was $3.8 million, compared to Adjusted EBITDA of $5.3 million in the prior year period Reiterates CFR and Adjusted EBITDA guidance for 2021PHILADELPHIA, Aug. 09, 2021 (GLOBE NEWSWIRE) — Hill International, Inc. (NYSE:HIL) (“Hill” or the “Company”), delivering the infrastructure...